Prospect: information for the patient
Alfuzosina Teva-ratiopharm 10 mg prolonged-release tablets EFG
alfuzosin hydrochloride
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
1. What is Alfuzosina Teva-ratiopharm 10 mg and for what it is used
2. What you need to know before starting to take Alfuzosina Teva-ratiopharm 10 mg
3. How to take Alfuzosina Teva-ratiopharm 10 mg
4. Possible adverse effects
5. Storage of Alfuzosina Teva-ratiopharm 10 mg
6. Contents of the package and additional information
This medication belongs to a group of medicines called alpha-blockers.
It is used to treat the functional symptoms of benign prostatic hyperplasia (enlarged prostate). An enlarged prostate can cause urinary problems such as frequent urination and difficulty urinating.
Do not take Alfuzosina Teva-ratiopharm 10 mg prolonged-release tablets
Warnings and precautions
Before starting treatment with Alfuzosina Teva-ratiopharm 10 mg, your doctor may perform some tests to rule out the presence of other diseases that may cause the same symptoms as benign prostatic hyperplasia. Before treatment and at regular intervals, a rectal examination may be performed and, if necessary, blood tests may be done.
Consult your doctor or pharmacist before starting to take Alfuzosina Teva-ratiopharm 10 mg
Normally, these effects only last a short time and occur at the beginning of treatment.
Normally, it is not necessary to interrupt treatment.
Consult your doctor if you suffer from this disease or are taking other medicines.
Alfuzosina, like other medicines in the same family, may cause priapism (persistent and painful erection of the penis). If this happens, go immediately to an emergency service to be treated.
Consult your doctor or pharmacist even if any of the circumstances mentioned above have occurred at any time.
Surgery while taking Alfuzosina
Other medicines and Alfuzosina Teva-ratiopharm
Inform your doctor or pharmacist if you are taking, have taken recently other medicines or may need to take any other medicine, even those purchased without a prescription.
Certain medicines, such as those listed below, may increase the risk of hypotension (drop in blood pressure) when taken at the same time as Alfuzosina Teva-ratiopharm.
Medicines that should not be used:
Medicines that should be taken with caution:
In addition, the administration of general anesthetics to patients treated with alfuzosina may cause instability of blood pressure, so, in the event of surgical intervention, you should inform the anesthetist of the use of Alfuzosina Teva-ratiopharm.
Alfuzosina Teva-ratiopharm 10 mg with food and drinks
The tablets should be taken after a meal.
Pregnancy and Breastfeeding
Alfuzosina Teva-ratiopharm 10 mg is only indicated for men.
Driving and operating machinery
At the beginning of treatment with Alfuzosina Teva-ratiopharm 10 mg, you may feel dizzy, lightheaded or weak. Do not drive or operate machinery or perform any hazardous task until you know how you respond to treatment.
Alfuzosina Teva-ratiopharm 10 mg contains lactose
This medicine contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with him before taking this medicine.
Followexactly the administration instructions for this medication as indicated by your doctor or pharmacist. Consult your doctor or pharmacist if you have any doubts.
AdultsThe recommended dose is one prolonged-release tablet (10 mg of alfuzosin) once a day, which is the maximum daily dose. Take the first tablet at bedtime. Take the tablets after the same meal every day and swallow them whole with a sufficient amount of liquid. Do not crush, chew, or divide the tablets.
Older patients
No dosage adjustment is required for elderly patients (over 65 years old).
Renal insufficiency
In patients with mild or moderate renal insufficiency, it is recommended to start treatment with a lower dose, which can be increased to 10 mg based on clinical response.
In patients with severe renal insufficiency, it is recommended not to use Alfuzosin Teva-ratiopharm 10 mg because there are no clinical safety data to support the safety of the medication in this patient group.
Use in children and adolescents
The efficacy of alfuzosin in children or adolescents from 2 to 16 years has not been demonstrated. Therefore, alfuzosin is not indicated in this patient group.
If you take more Alfuzosin Teva-ratiopharm 10 mg prolonged-release tablets than you should:If you take large amounts of Alfuzosin Teva-ratiopharm 10 mg, your blood pressure may drop suddenly and you may feel dizzy or even faint. If you start to feel dizzy, sit or lie down until you feel better. If symptoms do not improve, call your doctor as blood pressure drop may require hospital treatment.
Contact your doctor, pharmacist, or call the Toxicology Information Service, Phone: 91-562 04 20, indicating the medication and the amount taken.
If you forgot to take Alfuzosin Teva-ratiopharm 10 mg prolonged-release tablets:Do not take a double dose to make up for the missed dose, as this may cause a sudden drop in blood pressure, especially if you are taking blood pressure-lowering medications. Take the next tablet as instructed.
If you interrupt treatment with Alfuzosin Teva-ratiopharm 10 mg prolonged-release tablets
You should not interrupt or stop taking Alfuzosin Teva-ratiopharm 10 mg without first consulting your doctor. If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them:
Frequent (may affect up to 1 in 10 people):
Less frequent (may affect up to 1 in 100 people):
Very rare (may affect up to 1 in 10,000 people):
Frequency not known (cannot be estimated from available data):
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use website: www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box or blister after CAD. The expiration date is the last day of the month indicated.
Keep the blister in the original packaging to protect it from light.
Store below 30°C.
For HDPE bottles:
The product's expiration date after the first opening is 1 year, but not later than the expiration date included in the case or blister after CAD.
Medicines should not be thrown away through drains or in the trash. Dispose of the containers and medicines you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Alfuzosina Teva-ratiopharm 10 mg prolonged-release tablets
The active ingredient is alfuzosin hydrochloride. Each prolonged-release tablet contains 10 mg of alfuzosin hydrochloride.
Appearance of Alfuzosina Teva-ratiopharm 10 mg prolonged-release tablets and content of the container
Alfuzosina Teva-ratiopharm 10 mg is a prolonged-release round, white tablet in
blister packs (PVC/PVDC/aluminum) of 10, 28, 30, 50, 90, or 100 tablets per container, or bottles (HDPE) of 100 tablets per container. All container sizes may not be marketed.
Holder of the Marketing Authorization
Teva Pharma S.L.U.
C/ Anabel Segura, 11 Edificio Albatros B, 1st floor
28108 Alcobendas (Madrid)
Responsible for manufacturing
Merckle GmbH
Ludwig-Merckle Str. 3
89143 Blaubeuren / Germany
This medicine is registered in the Member States of the EEA with the following names
Estonia: ALFUZOSIN-TEVA
Latvia: Alfuzosin-Teva 10 mg prolonged-action tablets
Lithuania: Alfuzosin-Teva 10 mg prolonged-release tablets
Portugal: Alfuzosina Teva 10 mg prolonged-release tablet
Spain: Alfuzosina Teva 10 mg prolonged-release tablets EFG
United Kingdom: Fuzatal XL 10mg prolonged-release tablets
This leaflet was revised in September 2022
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.